Antidepressants in pregnancy: A review of commonly prescribed medications

Obstetrical and Gynecological Survey

Volumn 66, Issue 12, 2011, Pages 777-787

  Patil, Avinash S ^a   Kuller, Jeffrey A ^a   Rhee, Eleanor H J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CODEINE; DESVENLAFAXINE; DRUG METABOLITE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; NORFLUOXETINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; ANOREXIA; ANXIETY DISORDER; APNEA; BEDTIME DOSAGE; BODY TEMPERATURE DISORDER; BREAST FEEDING; BREATHING DISORDER; CARDIOVASCULAR MALFORMATION; COLIC; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CRYING; CYANOSIS; DEMETHYLATION; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG MONITORING; DRUG SAFETY; EAR DISEASE; FEEDING; FEEDING DISORDER; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; GLUCOSURIA; GROWTH DISORDER; HUMAN; HYPERGLYCEMIA; HYPERREFLEXIA; HYPOGLYCEMIA; INFANT DISEASE; INSOMNIA; IRRITABILITY; KIDNEY FUNCTION; LACTATION; LIVER DYSFUNCTION; MAJOR DEPRESSION; MORNING DOSAGE; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NECROTIZING ENTEROCOLITIS; NERVOUSNESS; NEWBORN DISEASE; OBSESSIVE COMPULSIVE DISORDER; PATIENT COUNSELING; PERINATAL DEPRESSION; PERINATAL PERIOD; PERSISTENT PULMONARY HYPERTENSION; PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN; PREGNANCY; PREMATURE LABOR; PRENATAL CARE; PRESCRIPTION; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SECOND TRIMESTER PREGNANCY; SEDATION; SEIZURE; SEROTONIN UPTAKE; SIDE EFFECT; SLEEP DISORDER; SMALL FOR DATE INFANT; SOMNOLENCE; SPONTANEOUS ABORTION; STIMULUS RESPONSE; SUCKLING; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BREAST FEEDING; DEPRESSION; DRUG LABELING; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84555196737     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31823e0cbf     Document Type: Review

References (70)

1. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103:698-709. (Pubitemid 40459031)
2. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005:1-8.
3. Banti S, Mauri M, Oppo A, et al. From the third month of pregnancy to 1 year postpartum. Prevalence, incidence, recurrence, and new onset of depression. Results from the Perinatal Depression-Research & Screening Unit study. Compr Psychiatry. 2011;52:343-351.
4. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:924-930. (Pubitemid 30412343)
5. Meltzer-Brody S. New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. Dialogues Clin Neurosci. 2011;13:89-100.
6. Wadhwa PD, Dunkel-Schetter C, Chicz-DeMet A, et al. Prenatal psychosocial factors and the neuroendocrine axis in human pregnancy. Psychosom Med. 1996;58:432-446. (Pubitemid 26349890)
7. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev. 2006;29:445-455. (Pubitemid 43811827)
8. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114:703-713.
9. Goedhart G, Snijders AC, Hesselink AE, et al. Maternal depressive symptoms in relation to perinatal mortality and morbidity: results from a large multiethnic cohort study. Psychosom Med. 2010;72:769-776.
10. Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol. 2000;95:487-490. (Pubitemid 30139565)
11. LeWinn KZ, Stroud LR, Molnar BE, et al. Elevated maternal cortisol levels during pregnancy are associated with reduced childhood IQ. Int J Epidemiol. 2009;38:1700-1710.
12. Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol. 2001;95:127-131. (Pubitemid 32208683)
13. Felix RJ, Jones KL, Johnson KA, et al. Postmarketing surveillance for drug safety in pregnancy: the Organization of Teratology Information Services project. Birth Defects Res A Clin Mol Teratol. 2004;70:944-947. (Pubitemid 40030371)
14. Gendron MP, Martin B, Oraichi D, et al. Health care providers' requests to Teratogen Information Services on medication use during pregnancy and lactation. Eur J Clin Pharmacol. 2009;65:523-531.
15. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy-15 years experience of ENTIS. Reprod Toxicol. 2005;20:331-343. (Pubitemid 40943555)
16. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507. (Pubitemid 43200344)
17. Patel SR, Wisner KL. Decision making for depression treatment during pregnancy and the postpartum period. Depress Anxiety. 2011;28:589-595.
18. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 2000;157:1933-1940.
19. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. In press.
20. Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196: 544 e1-e5.
21. Aronoff GR, Bergstrom RF, Pottratz ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36:138-144. (Pubitemid 14091704)
22. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11:51-57. (Pubitemid 30228410)
23. Altshuler LL, Hendrick VC. Pregnancy and psychotropic medication: changes in blood levels. J Clin Psychopharmacol. 1996;16:78-80. (Pubitemid 26059172)
24. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150:1541-1542. (Pubitemid 23289315)
25. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73:330-337. (Pubitemid 36403593)
26. Sit D, Perel JM, Luther JF, et al. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. J Clin Psychopharmacol. 2010;30:381-386.
27. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72:184-191. (Pubitemid 35034496)
28. Freeman MP, Nolan PE Jr, Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008;28:646-653.
29. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20(suppl 4):54-59. (Pubitemid 44576659)
30. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354:579-587. (Pubitemid 43209105)
31. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol. 2006;21:221-222. (Pubitemid 43294548)
32. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075-1085. (Pubitemid 350020060)
33. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29:918-926. (Pubitemid 47223423)
34. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol. 2009;29:555-560.
35. Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics. 2009;124:e547-e556.
36. Berle JO, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry. 2004;65:1228-1234.
37. Rampono J, Hackett LP, Kristensen JH, et al. Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk. Br J Clin Pharmacol. 2006;62:316-322. (Pubitemid 44215532)
38. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics. 1992;89(4 pt 1):676-677.
39. Epperson CN, Jatlow PI, Czarkowski K, et al. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding motherinfant pairs. Pediatrics. 2003;112:e425.
40. Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry. 1990;51:169. (Pubitemid 20129744)
41. Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999;48:521-527. (Pubitemid 29454232)
42. Kristensen JH, Hackett LP, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact. 2002;18:139-143.
43. Gentile S. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding. Arch Womens Ment Health. 2006;9:158-159. (Pubitemid 44020375)
44. Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol. 1999;48:142-147. (Pubitemid 29349448)
45. Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry. 2001;179:163-166. (Pubitemid 32756499)
46. Hostetter AL, Stowe ZN, Cox M, et al. A novel system for the determination of antidepressant concentrations in human breast milk. Ther Drug Monit. 2004;26:47-52. (Pubitemid 38140911)
47. Ohman R, Hagg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry. 1999;60:519-523. (Pubitemid 29413471)
48. Dodd S, Stocky A, Buist A, et al. Sertraline analysis in the plasma of breast-fed infants. Aust N Z J Psychiatry. 2001;35: 545-546. (Pubitemid 32798779)
49. Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry. 1997;154:1255-1260. (Pubitemid 27369177)
50. Kristensen JH, Ilett KF, Dusci LJ, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol. 1998;45:453-457. (Pubitemid 28227346)
51. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry. 1998;59(suppl 2):41-52. (Pubitemid 28155488)
52. Wisner KL, Perel JM, Blumer J. Serum sertraline and Ndesmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry. 1998;155:690-692. (Pubitemid 28225413)
53. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry. 1996;153:1132-1137. (Pubitemid 26299830)
54. Klier CM, Mossaheb N, Saria A, et al. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. J Clin Psychopharmacol. 2007; 27:720-722. (Pubitemid 351339468)
55. Treichel M, Schwendener Scholl K, Kessler U, et al. Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis? World J Pediatr. 2009;5:65-67.
56. Pakalapati RK, Bolisetty S, Austin MP, et al. Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health. 2006;42:737-738. (Pubitemid 44581631)
57. Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol. 1998;45:459-462. (Pubitemid 28227347)
58. Ilett KF, Kristensen JH, Hackett LP, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol. 2002; 53:17-22. (Pubitemid 34117734)
59. Lobo ED, Loghin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet. 2008;47:103-109.
60. Earhart AD, Patrikeeva S, Wang X, et al. Transplacental transfer and metabolism of bupropion. J Matern Fetal Neonatal Med. 2010;23:409-416.
61. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:474-484. (Pubitemid 46824268)
62. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol. 2010;203:52.e1-52.e6.
63. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192: 932-936. (Pubitemid 40311292)
64. Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet. 2003;268:219-221. (Pubitemid 36988464)
65. Baab SW, Peindl KS, Piontek CM, et al. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry. 2002;63:910-911. (Pubitemid 35231731)
66. Briggs GG, Samson JH, Ambrose PJ, et al. Excretion of bupropion in breast milk. Ann Pharmacother. 1993;27:431-433. (Pubitemid 23123890)
67. Kristensen JH, Ilett KF, Rampono J, et al. Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Pharmacol. 2007;63:322-327.
68. Tonn P, Reuter SC, Hiemke C, et al. High mirtazapine plasma levels in infant after breast feeding: case report and review of the literature. J Clin Psychopharmacol. 2009;29:191-192.
69. Aichhorn W, Whitworth AB, Weiss U, et al. Mirtazapine and breast-feeding. Am J Psychiatry. 2004;161:2325.
70. Klier CM, Mossaheb N, Lee A, et al. Mirtazapine and breastfeeding: maternal and infant plasma levels. Am J Psychiatry. 2007;164:348-349.